-- ADVENT-AML (CHM 0201 + Azacitidine + Venetoclax) Phase 1B clinical trial now open to enrollment at The University of Texas MD Anderson Cancer Center
-- Enrolment open to patients with relapsed / refractory Acute Myeloid Leukemia (AML), before the trial recruits up to 20 patients with newly diagnosed AML
-- ADVENT-AML trial is the first clinical trial to evaluate NK cells in combination with the current AML standard of care therapy
Sydney, Australia, 15 January 2024: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to announce that the Phase 1B ADVENT-AML clinical trial is now open to enrollment at The University of Texas MD Anderson Cancer Center. The ADVENT-AML Phase 1B study is evaluating Chimeric’s off-the-shelf universal donor NK cell therapy CHM 0201 in combination with standard of care therapy for patients with newly diagnosed Acute Myeloid Leukemia (AML).
The ADVENT-AML (NCT05834244) Phase 1B clinical trial is an investigator-initiated study at The University of Texas MD Anderson Cancer Center under Principal Investigator Abhishek Maiti MD, Assistant Professor in the Department of Leukemia.
For more information, download the attached PDF.
Download this document
